Log In
Monday 21st May 2018

NICE rejects Bayer liver cancer drug again

9th September 2009

The National Institute for Health and Clinical Excellence (NICE) has again rejected Bayer's drug Nexavar for treating liver cancer on the NHS.

This is despite a revised charging scheme from the company and is a further setback to Bayer and its partner Onyx Pharmaceuticals, which have already seen Nexavar turned down by the NICE to treat kidney cancer. Bayer said the decision on its drug, which is known generically as sorafenib, for the treatment of hepatocellular carcinoma was a blow to patients.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: NICE rejects Bayer liver cancer drug again
Author: Mark Nicholls
Article Id: 12602
Date Added: 9th Sep 2009


Reuters News

Recent Related Articles

Energy drinks ban in the UK


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018